Research programme: intranasal smallpox vaccine - BlueWillow Biologics
Alternative Names: Transmucosal smallpox vaccine - BlueWillow BiologicsLatest Information Update: 09 May 2018
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Smallpox
Most Recent Events
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Smallpox(Prevention) in USA (Intranasal)
- 26 Feb 2008 Preclinical trials in Smallpox in USA (Intranasal)